UCBJF:OTCMKTS
UCB SA
235,94 $
0,00%
(0,00) 1D
13. okt., 10:35:17 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za UCBJF …
Tržna kapitalizacija
39,29 mrd.
Povprečni promet
142,00
Promet
180,00
52-tedenski najvišji tečaj
345,39 $
52-tedenski najnižji tečaj
219,60 $
Beta
0,58
Št. izdanih delnic
194,51 mio.
Št. zaposlenih
9 tis.
Tržna kapitalizacija
39,29 mrd.
Povprečni promet
142,00
Promet
180,00
52-tedenski najvišji tečaj
345,39 $
52-tedenski najnižji tečaj
219,60 $
Beta
0,58
Št. izdanih delnic
194,51 mio.
Št. zaposlenih
9 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
ad-hoc-news.de
·
pred 8 urami
UCB dedicates Georgia site. UCB stock sits 30.78 percent below its high
ad-hoc-news.de
·
pred 11 urami
UCB launches Wear It Out program: UCB stock pre-market at EUR 198.60
ad-hoc-news.de
·
pred 1 dnevom
ING sets EUR 304.00 target for UCB stock with 48.87 percent upside
ad-hoc-news.de
·
pred 1 dnevom
UCB stock pre-market at EUR 203.40
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Vizitka: UCB SA
Generalni direktorJean-Christophe Tellier
Št. zaposlenih9 tis.
Ustanovljeno18. jan. 1928
Sedež-
Sektor-
Spletno mestoucb.com